India, July 15 -- SciSparc Ltd. (SPRC) announced that its subsidiary, NeuroThera Labs Inc. (NTLX.V), a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders, initiated its Phase IIb clinical trial site for SCI-110, its investigational candidate for the treatment of Tourette Syndrome (TS) in adults.
Tourette syndrome (TS) is a neurological disorder characterized by repeated, involuntary movements and vocalizations called tics. Tourette syndrome affects more boys than girls, and the first symptoms usually occur between the ages of 5 and 10 years, generally in the head and neck area. (Source: nih.gov)
SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in one d...